Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats

Rajesh Kumar Suman,1 Ipseeta Ray Mohanty,1 Ujwala Maheshwari,2 Manjusha K Borde,1 YA Deshmukh1 1Department of Pharmacology, 2Department of Pathology, MGM Medical College, Kamothe, Navi Mumbai, India Background: Mangiferin (MNG) is known to possess antidiabetic and antioxidant activity. However, ther...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Suman RK, Mohanty IR, Maheshwari U, Borde MK, Deshmukh YA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Mangiferin Diabetes Metabolic Syndrome High Fat Diet Streptozotocin Rats Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/f155ada8cef845c083ab819c9ee54af3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f155ada8cef845c083ab819c9ee54af3
record_format	dspace
spelling	oai:doaj.org-article:f155ada8cef845c083ab819c9ee54af32021-12-02T01:37:55ZNatural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats1178-7007https://doaj.org/article/f155ada8cef845c083ab819c9ee54af32016-08-01T00:00:00Zhttps://www.dovepress.com/natural--dipeptidyl-peptidase-iv-inhibitor-mangiferin-mitigates-diabet-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Rajesh Kumar Suman,1 Ipseeta Ray Mohanty,1 Ujwala Maheshwari,2 Manjusha K Borde,1 YA Deshmukh1 1Department of Pharmacology, 2Department of Pathology, MGM Medical College, Kamothe, Navi Mumbai, India Background: Mangiferin (MNG) is known to possess antidiabetic and antioxidant activity. However, there is no experimental evidence presently available in the literature with regard to its ameliorating effects on diabetes mellitus coexisting with metabolic syndrome.Objective: The present study was designed to evaluate the protective effects of MNG on various components of metabolic syndrome with diabetes as an essential component.Material and methods: Adult Wistar rats were fed high-fat diets for 10 weeks and challenged with streptozotocin (40 mg/kg) at week three (high-fat diabetic control group). After the confirmation of metabolic syndrome in the setting of diabetes, MNG 40 mg/kg was orally fed to these rats from the fourth to tenth week.Results: The treatment with MNG showed beneficial effects on various components of metabolic syndrome, such as reduced dyslipidemia (decreased triglyceride, total cholesterol, low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol) and diabetes mellitus (reduced blood glucose and glycosylated hemoglobin). In addition, an increase in serum insulin, C-peptide, and homeostasis model assessment-β and a reduction in homeostasis model assessment of insulin resistance-IR were observed in MNG-treated group compared with high-fat diabetic control group. MNG was also found to be cardioprotective (reduction in creatine phosphokinase-MB levels, atherogenic index, high-sensitivity C-reactive protein). Reduction in serum dipeptidyl peptidase--IV levels in the MNG-treated group correlated with improvement in insulin resistance and enhanced β-cell function.Conclusion: The present study has demonstrated antidiabetic, hypolipidemic, and cardioprotective effects of MNG in the setting of diabetes with metabolic syndrome. Thus, MNG has the potential to be developed as a natural alternative to synthetic dipeptidyl peptidase-IV inhibitors beneficial in this comorbid condition. Keywords: mangiferin, diabetes, metabolic syndrome, high-fat diet, streptozotocin, ratsSuman RKMohanty IRMaheshwari UBorde MKDeshmukh YADove Medical PressarticleMangiferinDiabetesMetabolic SyndromeHigh Fat DietStreptozotocinRatsSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 9, Pp 261-272 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Mangiferin Diabetes Metabolic Syndrome High Fat Diet Streptozotocin Rats Specialties of internal medicine RC581-951
spellingShingle	Mangiferin Diabetes Metabolic Syndrome High Fat Diet Streptozotocin Rats Specialties of internal medicine RC581-951 Suman RK Mohanty IR Maheshwari U Borde MK Deshmukh YA Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
description	Rajesh Kumar Suman,1 Ipseeta Ray Mohanty,1 Ujwala Maheshwari,2 Manjusha K Borde,1 YA Deshmukh1 1Department of Pharmacology, 2Department of Pathology, MGM Medical College, Kamothe, Navi Mumbai, India Background: Mangiferin (MNG) is known to possess antidiabetic and antioxidant activity. However, there is no experimental evidence presently available in the literature with regard to its ameliorating effects on diabetes mellitus coexisting with metabolic syndrome.Objective: The present study was designed to evaluate the protective effects of MNG on various components of metabolic syndrome with diabetes as an essential component.Material and methods: Adult Wistar rats were fed high-fat diets for 10 weeks and challenged with streptozotocin (40 mg/kg) at week three (high-fat diabetic control group). After the confirmation of metabolic syndrome in the setting of diabetes, MNG 40 mg/kg was orally fed to these rats from the fourth to tenth week.Results: The treatment with MNG showed beneficial effects on various components of metabolic syndrome, such as reduced dyslipidemia (decreased triglyceride, total cholesterol, low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol) and diabetes mellitus (reduced blood glucose and glycosylated hemoglobin). In addition, an increase in serum insulin, C-peptide, and homeostasis model assessment-β and a reduction in homeostasis model assessment of insulin resistance-IR were observed in MNG-treated group compared with high-fat diabetic control group. MNG was also found to be cardioprotective (reduction in creatine phosphokinase-MB levels, atherogenic index, high-sensitivity C-reactive protein). Reduction in serum dipeptidyl peptidase--IV levels in the MNG-treated group correlated with improvement in insulin resistance and enhanced β-cell function.Conclusion: The present study has demonstrated antidiabetic, hypolipidemic, and cardioprotective effects of MNG in the setting of diabetes with metabolic syndrome. Thus, MNG has the potential to be developed as a natural alternative to synthetic dipeptidyl peptidase-IV inhibitors beneficial in this comorbid condition. Keywords: mangiferin, diabetes, metabolic syndrome, high-fat diet, streptozotocin, rats
format	article
author	Suman RK Mohanty IR Maheshwari U Borde MK Deshmukh YA
author_facet	Suman RK Mohanty IR Maheshwari U Borde MK Deshmukh YA
author_sort	Suman RK
title	Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
title_short	Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
title_full	Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
title_fullStr	Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
title_full_unstemmed	Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
title_sort	natural dipeptidyl peptidase-iv inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/f155ada8cef845c083ab819c9ee54af3
work_keys_str_mv	AT sumanrk naturaldipeptidylpeptidaseivinhibitormangiferinmitigatesdiabetesandmetabolicsyndromeinducedchangesinexperimentalrats AT mohantyir naturaldipeptidylpeptidaseivinhibitormangiferinmitigatesdiabetesandmetabolicsyndromeinducedchangesinexperimentalrats AT maheshwariu naturaldipeptidylpeptidaseivinhibitormangiferinmitigatesdiabetesandmetabolicsyndromeinducedchangesinexperimentalrats AT bordemk naturaldipeptidylpeptidaseivinhibitormangiferinmitigatesdiabetesandmetabolicsyndromeinducedchangesinexperimentalrats AT deshmukhya naturaldipeptidylpeptidaseivinhibitormangiferinmitigatesdiabetesandmetabolicsyndromeinducedchangesinexperimentalrats
_version_	1718402991282716672

Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats

Ejemplares similares